Mission Statement

The NIDCD National Temporal Bone, Hearing and Balance Pathology Resource Registry was established in 1992 by the National Institute on Deafness and Other Communication Disorders (NIDCD) of the National Institutes of Health (NIH) to continue and expand upon the former National Temporal Bone Banks (NTBB) Program. The Registry promotes research on hearing and balance disorders and serves as a resource for the public and scientific communities about research on the pathology of the human auditory and vestibular systems.

Featured Research

Invasion Patterns of External Auditory Canal Squamous Cell Carcinoma: A Histopathology Study

Temporal bone (TB) malignant neoplasms are rare, occurring in 1:5000-20,000 ear disorders1. These malignant tumors can be categorized as primary or secondary. Primary TB malignant tumors originate in the TB, most commonly in the external auditory canal (EAC). Secondary tumors arise from extra-TB tissue and invade it by means of local extension or metastatic spread. The most common advanced stage malignancy is squamous cell carcinoma (SCC) of the EAC2.

EAC SCC tends to expand through consistent patterns such as invasion of compact bone, along blood vessels, cranial nerves and areas of osseous weaknesses like sutures and along the TB air cells tracks.

The aim of this study is to examine the invasion patterns of advanced stage SCC of the EAC and to compare the histological findings to clinical data. To the best of our knowledge, this is the first analysis of a series of TBs of patients with primary SCC of the TB.

Nine TBs from 9 patients were included in the cohort. Patients were diagnosed from 1968 to 2010. All cases presented with T4 stage disease according to the modified Pittsburgh...
The staging system \(^3\) (Figure 1). The demographics and clinical presentation are found in Table 1. The most common presenting symptom was hearing loss (7 patients), the majority of which was severe to profound (5 patients). The most common otoscopic finding was obstructing mass EAC (5 patients).

Several soft tissue elements within the TB were found to serve as barriers, limiting tumor invasion. The tympanic membrane was found to limit tumor extension medially in 4 patients. In these patients, the pathway of spread from the EAC to the middle ear (ME) was through the bony posterior EAC wall, to the mastoid air cells system (MACS) and the antrum. In five patients the tumor invaded the ME from the EAC directly, through the TM. The vestibulo-stapedial (annular) ligament was found to be a significant anatomic barrier for tumor spread from the middle to the inner ear. The resistance against tumor spread was so effective, that otic capsule invasion was seen adjacent to intact vestibulo-stapedial ligament. The round window membrane (RWM) was not invaded, although its niche was filled with tumor in 3 subjects. Examples of the relationship between these soft tissue barriers and tumor extension are shown in figure 2.

Several patterns of tumor spread were identified: besides serving as a route to the ME, the MACS was found to serve as a tumor conduit to the tegmen mastoideum and overlying dura, the posterior fossa dura, the vertical segment of the facial nerve, the ME and the lateral semicircular canal. The supra and infra labyrinthine pneumatization patterns allowed direct routes of tumor spread to the petrous apex (PA), leaving the otic capsule intact and most easily demonstrated in the vertical oriented histological preparations. The petromastoid canal served as an additional route to the PA via the subarcuate route (Figure 3). Trans labyrinthine PA invasion was seen in 2 patients. Once in the ME, tumors tended to spread to the anterior and posterior attic. We found no evidence that surgical modification of the TB anatomy created iatrogenic pathways for tumor spread. The otic capsule itself was involved in 6 patients. The most common locus of otic capsule invasion was the cochlea, followed by the lateral semicircular canal (LSCC) and vestibule.

The tympanic segment of facial nerve was involved in 5 subjects and the vertical segment was involved in 3, resulting in varying degrees of facial nerve weakness. Wallerian degeneration was present distal to the proximal-most site of neural invasion (Figure 4).

Primary TB SCC is a rare, aggressive tumor, comprising 80% of primary TB malignancies \(^4,5\). This tumor carries a substantial risk for morbidity and mortality because of its aggressive nature, location at the skull base and the common delay in diagnosis \(^6\). Early symptoms can be easily attributed to more common conditions such as otitis media and externa. This delay is likely to have a detrimental effect on treatment and outcome.

---

Table 1

<table>
<thead>
<tr>
<th>#</th>
<th>Gender</th>
<th>Side</th>
<th>Age at Diagnosis</th>
<th>Hearing Loss</th>
<th>Vertigo</th>
<th>Tinnitus</th>
<th>CNVI Poly [HB scale]</th>
<th>Otoscopy</th>
<th>Age of Death</th>
<th>Cause of Death</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>R</td>
<td>62</td>
<td>Moderate</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>Blocked EAC</td>
<td>66</td>
<td>Distant metastasis</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>R</td>
<td>70</td>
<td>Profound</td>
<td>-</td>
<td>+</td>
<td>6</td>
<td>Blocked EAC</td>
<td>70</td>
<td>Brain extension</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>R</td>
<td>73</td>
<td>Moderate</td>
<td>+</td>
<td>-</td>
<td>6</td>
<td>Blocked EAC</td>
<td>79</td>
<td>NA</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>R</td>
<td>56</td>
<td>Profound</td>
<td>-</td>
<td>+</td>
<td>3</td>
<td>NA</td>
<td>57</td>
<td>Cerebellar Abscess</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>L</td>
<td>55</td>
<td>Severe</td>
<td>+</td>
<td>+</td>
<td>6</td>
<td>NA</td>
<td>56</td>
<td>NA</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>L</td>
<td>46</td>
<td>Profound</td>
<td>-</td>
<td>+</td>
<td>2</td>
<td>Blocked EAC</td>
<td>49</td>
<td>Massive MI</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>L</td>
<td>51</td>
<td>Severe</td>
<td>NA</td>
<td>-</td>
<td>1</td>
<td>Post Auricular Mass + Blocked EAC</td>
<td>52</td>
<td>Brain Extension</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>R</td>
<td>80</td>
<td>NA</td>
<td>+</td>
<td>NA</td>
<td>3</td>
<td>Bleeding from EAC</td>
<td>81</td>
<td>Brain Extension</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>L</td>
<td>80</td>
<td>NA</td>
<td>No</td>
<td>+</td>
<td>NA</td>
<td>Draining ear</td>
<td>84</td>
<td>Pneumonia</td>
</tr>
</tbody>
</table>

NA: Not available; CNVI: Cranial nerve 7; M: Male; F: Female; SCC: Squamous cell carcinoma; MI: Myocardial infarction; EAC: external auditory canal; R: Right, L: Left; HB: House-Brackmann

---

The reports in the Registry Newsletter are not peer reviewed.
FIGURE 1: Malignant invasion throughout the temporal bone, indicating stage T4. (A-I) These H&E horizontal oriented histological preparations belong to patient #2. (A) Middle ear and petrous apex air cells are filled with the tumor. Stapes is partially subluxated. The otic capsule is invaded near the basal turn of the cochlea and internal auditory canal (asterisk). (B) High power magnification of figure 1A. The vestibular-stapedial (annular) ligament is intact, limiting tumor invasion to the vestibule (arrow). The tumor invades the otic capsule towards the cochlea and vestibule. (C) Low power magnification of the same TB. The tumor fills the external ear canal, mastoid and petrous apex. The posterior fossa dura over the mastoid is partially dehiscent. (D) The tumor invades the round window niche and the otic capsule overlying the posterior semicircular canal and cochlea (arrows). (E) Low power magnification of the petrous apex. The tumor encases the carotid canal, which is partially dehiscent. (F) High power magnification of figure 1E. The tumor invades the tunica externa of the petrous segment of the carotid artery. (G) Petrous apex air cells and internal auditory canal are filled with tumor. (H) High power magnification of figure 1G. The internal auditory canal is partially invaded by the tumor, as well as the posterior fossa dura. (I) Pure tone audiogram of the same patient showing profound conductive hearing loss, with reduced discrimination.

FIGURE 2: Soft tissue barriers limit SCC spread throughout the TB. (A) H&E horizontal oriented histological preparations of patient #1. This patient was treated with high dose of XRT (120 Gy) to the TB, replacing the SCC by fibrotic mass. EAC is filled with fibrotic mass. The TM is intact, effectively preventing medial invasion. Mastoid is invaded through the EAC posterior wall. The facial nerve is intact. (B-F) H&E preparation from the temporal bone described in figure 1, belong to patient #2. (B) The mastoid is invaded by the tumor, totally destroying the air cells system. (C) Low power magnification of figure 2B. The dura is invaded, as well as the otic capsule around the vestibule, which is partially dehiscent. (D) The vestibular-stapedial ligament limits medial tumor extension to the vestibule. The tumor invades the otic capsule around the basal and medium cochlear turns (asterisk). (E) High power magnification of figure 2D. (F) The tumor fills the round window niche. The round window is intact, preventing tumor extension to the inner ear spaces.
Symptoms can point to TB sites with tumor spread. The triad of pain, bleeding and otorrhea is the classical presentation of TB cancer. Obstructing mass in the EAC is probably the most specific sign, especially when combined with facial nerve palsy.

Several anatomical routes and barriers for tumor spread were identified. Routes of cancer spread through the TB are highly dependent on TB pneumatization. Most of the published literature relates to cholesteatoma patterns of spread. However, there are several major differences between SCC and cholesteatoma, including cancer propensities to spread along nerves and the site of origin of the disease. Cholesteatoma originates from the TM (except when congenital, iatrogenic and blast-induced), whereas SCC may originate anywhere in the EAC. From the EAC tumor approaches the ME via the posterior tympanic segment, whether intact or perforated, or by means of invasion the middle ear cavity penetration. The intact TM was found to serve as a reliable tumor expansion barrier. In several specimens, it was impossible to determine if the tumor invaded and perforated a previously intact TM, or via a previously perforated TM. Another soft tissue barrier was found to be the vestibulo-stapedial ligament (VSL). An intact VSL was seen adjacent to otic capsule (promontory) invasion. The RWM was the second soft tissue barrier for inner ear cavity penetration.

The clinical importance of these anatomical barriers is the difference in surgical extent indicated in case of intact versus invaded barriers. Tumor confined to the EAC with some bone erosion (T1-T2) can be treated effectively with, a lateral TB resection (LTBR). In these cases LTBR with free pathological margins can save a patient from the need to be irradiated. Historically extensive en-bloc surgery (subtotal and total temporal bone resections) have been offered to patients with more advanced stage disease. However, en-bloc resection has not proven to have superior results as compared to procedures involving piecemeal dissection. These advanced stage disease ears usually requires the addition of radiation therapy. Once the TM is invaded and tumor extends to the ME, LTBR may be considered and subtotal TB resection (STTBR) or extended.
canal wall down tympano-mastoidectomy may be used as a more radical alternative, with similar cure rates. While inner ear is involved, through otic capsule invasion or through one of the inner ear windows, STTBR is indicated. Total TB resection (TTBR) is rarely indicated or performed nowadays. Defining the typical routes of SCC spread in the TB can help plan surgery, and direct efforts to TB subsites involved and anticipate possible location of disease not depicted by pre-operative imaging.

The neurotrophic nature of SCC can make the FN an additional route for tumor spread. The vertical (mastoid) segment is the most commonly involved followed by the tympanic segment.

**Take home messages:**

- TB histopathology can elucidate the extension routes of primary SCC carcinoma.
- The TM may serve as an incomplete barrier for tumor extension from the EAC to the ME.
- SCC does not tend to extended from the ME to the inner ear through the round window and vestibule-stapedial ligament.
- Tumors do tend to spread along the pre-existing TB air-tract routes.
- Well aerated TB may facilitate easier extension to the petrous apex.

**REFERENCES**

Liquid Biopsy of the Human Inner Ear and Interpretation of Novel Molecular Biomarkers in Patients With Vestibular Schwannomas: Measuring Mediators of Hearing Loss and Predicting Surgical Outcomes

Yin Ren1,2,3, Samuel Early1,2,3, Konstantina M. Stankovic1,2,4,5

1Department of Otolaryngology – Head and Neck Surgery and Eaton-Peabody Laboratories, Massachusetts Eye and Ear, Boston, MA, USA
2Department of Otolaryngology – Head and Neck Surgery, Harvard Medical School, Boston, MA, USA
3Division of Otolaryngology, Department of Surgery, School of Medicine, University of California, San Diego, CA, USA
4Program in Speech and Hearing Bioscience and Technology, Harvard Medical School, Boston, MA, USA
5Harvard Program in Therapeutic Science, Harvard Medical School, Boston, MA, USA

Vestibular schwannoma (VS) is the fourth most common intracranial tumor and constitutes 90% of all cerebellopontine angle (CPA) lesions1. It is a benign, slow-growing tumor arising from neoplastic Schwann cells lining the eighth cranial nerve. While the majority of VS occurs sporadically, a portion develops in association with neurofibromatosis type II (NF2). Despite its non-malignant nature, growing VS can be associated with significant morbidity including sensorineural hearing loss (SNHL) that affects up to 95% of patients, tinnitus, dizziness, increased rates of hospitalization, and poor mental health2. As tumors grow larger, they can cause additional symptoms such as palsy of the facial nerve and other cranial nerves, and potentially life-threatening complications including brainstem compression. The goal of contemporary VS management is to balance long-term tumor control, neurological function, and quality of life3. The standard treatment to remove the tumor is limited to surgery, as there are currently no FDA-approved pharmacotherapies for the treatment of VS or associated SNHL. Nonetheless, surgery can be associated with significant morbidities such as facial paralysis and deafness.

While numerous retrospective studies have attempted to identify clinical factors associated with disease severity and prognosis, there are no established reliable biomarkers to predict the degree of VS-associated SNHL or surgical outcomes after tumor resection. Clinical factors such as tumor size, tumor growth rate, and radiographic imaging features often suffer from poor sensitivity and specificity. Histological findings such as tumor proliferative index, while useful, are obtained only after tumor extirpation and do not offer prognostic information4. Moreover, there is great variability in surgical outcomes when patients undergo attempted microsurgical tumor resection. Factors such as tumor consistency, presence of cystic changes, and adhesions between the tumor capsule and the facial nerve have all been associated with an increased likelihood of subtotal tumor resection5. There have been over twenty clinical trials in the last 20 years on experimental therapies for NF1 and NF2, yet no biomarker-driven trial for NF2 has been performed6,7. Further, little is known about the molecular underpinnings of VS tumorigenesis that predisposes certain tumors towards incomplete resections.

Molecular biomarkers are objectively measured indicators of disease pathophysiology and have the potential to facilitate early detection of tumors, monitor disease progression, and impact the outcomes of treatment. Proteases, a class of enzymes that plays a fundamental role in both normal tissue remodeling and aberrant cellular growth, are candidates for biomarkers for VS8. In many human cancers, protease biomarkers have been well established to assess treatment response and even predict
Various members of the matrix metalloprotease (MMP) family have been implicated in promoting VS growth via angiogenesis, remodeling of the extracellular matrix, or enhancing growth factor signaling pathways. While these results are promising, the studies are limited to a small number of patients, are retrospective, and address only a particular protease candidate. Additionally, the majority of the published studies rely on immunohistochemical staining of tumor specimens rather than measuring serum levels as a readout, which precludes preoperative patient counseling and forecasting of clinical outcomes.

Since hearing loss is the most common consequence of VS, a clinically useful biomarker should differentiate tumors with good hearing from those with poor hearing. Furthermore, given the variability in clinical outcomes such as the extent of surgical resection, the biomarker should provide information about the likelihood of gross total tumor removal and the functional outcome of the facial nerve; two features that would greatly impact both long-term prognosis and the patient’s quality of life. A protease-based biomarker has the potential to outperform existing biomarkers which are often disease by-products with insufficient sensitivity, through leveraging the catalytic nature of protease signal amplification. Finally, a safe, reliable, minimally-invasive device for liquid biopsy of the inner ear would be necessary to collect diagnostically useful volumes of human perilymph.

To this end, we utilized transcriptomic data from the largest analysis to date of patients with VS to identify, for the first time, several proteases aberrantly expressed in VS genomes. Matrix metalloprotease 14 (MMP-14, also known as membrane type 1 MMP, MT1-MMP) was selected for further analysis and was found to have elevated expression and activity in an NF2-derived cell line, primary human VS cultures, and plasma samples from patients with VS (Figure 1). We ascertained the usefulness of MMP-14 as a potential biomarker by identifying its association with surgical outcomes. In a confirmatory investigation, the mechanism by which MMP-14 could cause VS-associated SNHL was investigated in murine cochlear explant models (Figure 2). Separately, we developed and tested a novel, minimally-invasive microneedle device in fresh human cadaveric temporal bones, which was shown to be capable of reliably collecting a perilymph sample of at least 1 μL in volume, either by transmastoid or transcanal tympanotomy approach to access

continued on page 8
the round window membrane, with minimal contamination from middle ear fluids (Figure 3); this volume has previously been shown to be diagnostically meaningful across multiple institutions\textsuperscript{14-16}. This device is designed with utmost safety in mind, including safeguards to monitor depth of penetration through the round window membrane and protect intracochlear structures. Trauma to the round window membrane with this device is minimal, smaller and more controlled than that typically associated with spontaneous perilymphatic fistula formation, and likely amenable to the highly successful repair strategies that are already available, such as placement of an absorbable gelatin sponge or a tiny fat graft\textsuperscript{17}.

In summary, we report the identification of multiple protease enzymes aberrantly expressed in VSs. Focusing on MMP-14, a member of the membrane-type MMP family with previously unknown roles in VS tumorigenesis or SNHL, we optimized a new functional assay to measure its proteolytic activity in plasma samples. MMP-14 levels correlated with preoperative hearing thresholds. In patients who underwent subtotal tumor removal, tumor secreted MMP-14 and plasma MMP-14 activity were both significantly elevated compared to patients with complete tumor resection. Mechanistically, we demonstrated direct neuronal damage, including loss of neurites and cochlear synapses, due to MMP-14 in a murine cochlear explant model.

Taken together, our findings expand the understanding of the role of proteases in VS and identify other candidate proteases from the largest pooled transcriptomic analysis to date that, when validated, could further enhance the diagnosis and

FIGURE 2: Application of MMP-14 to murine cochlear explants leads to loss of spiral ganglion neurites and cochlear synapses.

(A) Representative images of cochlear explants receiving no treatment (Ctrl, $n=10$ different explants), incubated with 10 ng/mL of murine MMP-14 (mMMP-14) for 72 h ($n=15$ different explants), or with 30 ng/mL of murine MMP-14 for 72 h ($n=16$ different explants). Myo7a (green) marks hair cells and NF-H (red) marks spiral ganglion neurites. Scale bar, 20 µm. (B) Representative images of untreated cochlear synapses (Ctrl, left column, $n=10$ explants), synapses after incubation with 10 ng/mL of mMMP-14 (middle column, $n=15$ explants), or 30 ng/mL of mMMP-14 (right column, $n=16$ explants). CtBP2 (red) marks pre-synaptic ribbons and PSD95 (green) marks post-synaptic densities. Scale bar, 10µm. C-E. Quantification of the number of IHCs per 100 µm (C), SGN fiber bundles per IHC measured 10 µm below the basolateral poles of hair cells, normalized to no-treatment controls (D), and CtBP2-PSD95 juxtapositions per IHC normalized to no-treatment controls (E). Error bars represent SEM. **P < 0.01, ***P < 0.001 by one-way ANOVA.
FIGURE 3: Positioning of the microneedle for perilymph sampling across the round window membrane.

(A-F) Demonstrate transmastoid facial recess approach in a left ear: (A) Access via transmastoid facial recess approach with identification of the facial nerve (f) and chorda tympani nerve (c), drilling of the round window overhang (o) to expose the round window membrane (*), with additional key landmarks including the stapedial tendon (s) and incudostapedial joint (j); (B) Same photo unlabeled; (C) Application of reference solution (blue) and placing of reference electrode into a mastoid air cell (not pictured); (D) Positioning of the microneedle adjacent to the round window membrane; (E) Perforation of the round window membrane and aspiration of perilymph; (F) Perforated round window membrane at low magnification; (G) Perforated round window membrane at high magnification, with arrowhead at site of perforation. (H-N) Demonstrate transtympanotomy approach in a right ear: (H) Round window access via transtympanotomy with lifting of the tympanic membrane, showing the round window niche (+) and fibrous annulus of the tympanic membrane (a); (I) Drilling of the round window overhang to expose the round window membrane (*); (J) Application of reference solution (blue) and placing of reference electrode into the inferior mesotympanum; (K) Positioning of the microneedle adjacent to the round window membrane; (L) Perforation of the round window membrane and aspiration of perilymph; (M) Perforated round window membrane at low magnification; (N) Perforated round window membrane at high magnification, with arrowhead at site of perforation. Scale bar = 1.0 mm for all pictures, assessed at depth of round window membrane.
personalized treatment of VS. The microneedle diagnostic platform which we have developed in parallel provides a potential avenue for minimally-invasive liquid biopsy of the inner ear, with potential to evaluate tumor-secreted MMP-14 levels in patients under consideration for VS resection to optimize counseling on expected outcomes. Predicting surgical outcomes using a minimally-invasive diagnostic can allow for more tailored selection of surgical candidates, and continued identification of predictive markers for VS or other SNHL-causing pathologies will further expand the value of this diagnostic platform.

REFERENCES


Want to go digital?

The editors of The Registry are now offering an electronic version of the newsletter for those who are interested. Mailed copies will continue to be distributed; however, if you prefer to receive an email with a PDF version of the newsletter instead, let us know and we will add you to our email list!

In addition, all current and previous issues can be found on our website at https://masseyeandear.org/tbregistry/research-resources

Interested in receiving digital newsletter copies?

Email Felipe Santos, MD, at Mass. Eye and Ear felipe_santos@meei.harvard.edu.
Otopathology Mini-Travel Fellowship Program

The NIDCD National Temporal Bone Registry’s mini-travel fellowships provide funds for research technicians and young investigators to visit a temporal bone laboratory for a brief educational visit, lasting approximately one week. The emphasis is on the training of research assistants, technicians, and junior faculty.

These fellowships are available to:
• U.S. hospital departments who aspire to start a new temporal bone laboratory
• Inactive U.S. temporal bone laboratories who wish to reactivate their collections
• Active U.S. temporal bone laboratories who wish to learn new research techniques

Up to two fellowship awards will be made each year ($1,000 per fellowship). The funds may be used to defray travel and lodging expenses. Applications will be decided on merit.

Interested applicants should submit the following:
• An outline of the educational or training aspect of the proposed fellowship (1–2 pages)
• Applicant’s curriculum vitae
• Letter of support from a temporal bone laboratory director or department chairman
• Letter from the host temporal bone laboratory indicating willingness to receive the traveling fellow

Applications should be submitted to:
Felipe Santos, MD
NIDCD Temporal Bone Registry
Massachusetts Eye and Ear
243 Charles Street, Boston, MA 02114
felipe_santos@meei.harvard.edu

Temporal Bone Removal Technicians Needed Nationwide!

Seeking trained autopsy technicians for the removal of temporal bones on an on-call basis. Technicians must be in the U.S. and are paid by case.

Interested? Email us at tbregistry@meei.harvard.edu
Free Brochures for your Office or Clinic about Temporal Bone Research and Donation

The Gift of Hearing and Balance: Learning About Temporal Bone Donation is a 16-page, full-color booklet that describes in detail the benefits of temporal bone research. It also answers commonly asked questions regarding the temporal bone donation process. Dimensions: 7”x10”

If you would like to display this brochure, please complete the form below and return it to the Registry by mail or fax. The brochures will be sent to you free of charge. Please circle the amount requested for each brochure or write in the amount if not listed.

The Gift of Hearing and Balance __________ 25  50  100

Name: ________________________________________________________________________________________________

Address: ________________________________________________________________________________________________

City, State, Zip: _________________________________________________________________________________________

Telephone: ____________________________________________________________________________________________

Mail or fax this form to the Registry at: NIDCD National Temporal Bone, Hearing and Balance Pathology Resource Registry
Massachusetts Eye and Ear, 243 Charles Street, Boston, MA 02114
Toll-free phone: (800) 822-1327, Fax: (617) 573-3838
Email: tblegistry@meei.harvard.edu